In this video series, three experts present the most important changes in the ESC/EAS dyslipidemia guidelines, lessons learned after 5 years of use with PCSK9 inhibitors, and implemental gaps in the use of lipid-lowering therapies.

Prof. Kastelein gives an introduction to the symposium about LDL-c lowering therapies with a specifiek focus on PSCK9 inhibition that was held during the virtual ESC 2020 congress.

Attainment of risk-based LDL-c goals in the ESC/EAS guidelines is low due to implementation gaps, but even with optimal statin use, combination therapy with PCSK9i is often needed to achieve 2019 LDL-c goals.

Prof. Stroes discusses the efficacy of PCSK9 inhibitors and which patients benefit most from LDL-c lowering (combination) therapies.

Prof. Mach discusses the concepts for lipid lowering treatment as defined in the 2019 ESC/EAS dyslipidemia guidelines.

Expert discussion on PCSK9i & LDL-c: Guidelines, Practice & Innovation.